Financials
Financial year 2025
ARICS from Machelen (Brab.), company number BE0465013149, closed financial year 2025 with a result of € 958,762 after tax. For that financial year ARICS recorded a gross margin of € 301,200 and equity of € 2.1 million. Compared with financial year 2024, the result moved from € 238,659 to € 958,762. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 29, 2026.
€ 2.1 million
▲ 63% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 958,762
▲ € 720,103 vs 2024
Profit after tax over the fiscal year.
€ 225,190
▲ 27% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 151,011 paid out
16 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
0.7
Average over the fiscal year, from the social balance sheet.
€ 87,805
▲ 3% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 18,595
▲ 31% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 32,787
▲ 3% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 94,990
▲ 284% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 286,097 | € 337,140 | € 287,694 | € 301,200 | ▲ 5% |
| Profit after taxes | € 264,677 | € 255,112 | € 238,659 | € 958,762 | ▲ € 720,103 |
| Equity | € 1,444,579 | € 1,377,898 | € 1,275,281 | € 2,083,032 | ▲ 63% |
| Total debts | € 108,567 | € 141,166 | € 64,342 | € 134,911 | ▲ 110% |
| Cash | € 341,277 | € 153,195 | € 177,120 | € 225,190 | ▲ 27% |
| Retained profit | € 1,383,079 | € 1,316,398 | € 1,213,781 | € 2,021,532 | ▲ 67% |
| Dividend | € 0 | € 321,793 | € 341,277 | € 151,011 | ▼ 56% |
| Balance sheet total | € 1,933,146 | € 1,799,064 | € 1,619,623 | € 2,217,943 | ▲ 37% |
| Employees (FTE) | - | - | 0.7 | 0.7 |
Key figures of ARICS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 May 2027.
What happened to ARICS?
What happened at ARICS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 958,762 (▲ € 720,103 vs 2024). Source: NBB ↗
- Lucas Vrambout became a director. NBB
- New establishment in Machelen (Brab.). KBO
- Start of the company according to the CBE. KBO
In short
From € 264,677 profit in 2022 to € 958,762 profit in 2025.
Paid € 505,272 in corporate taxes since 2022.
Best year ever: 2025, with € 958,762 profit.
Paid out € 814,081 in dividends to the owners in total.
Management
Behind ARICS is Lucas Vrambout. Lucas Vrambout is also behind ADOCS.
Directors
According to the 2025 annual accounts
since 2022
Establishments
Establishment units
Physical locations of this company
Peutiesesteenweg 111
1830 Machelen (Brab.)
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0465.013.149
- VAT number
- BE 0465.013.149
- Registered office
- Peutiesesteenweg 111, 1830 Machelen (Brab.)
- Names & denominations
- ARICS
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 28 December 1998
- Peppol
- Active · Active since 4 Nov 2025
- Activities · NACE
Overige hospitalisatiediensten
Detailhandel in farmaceutische producten
Groothandel in farmaceutische en medische artikelen
Detailhandel in cosmetica en toiletartikelen
Groothandel in parfumerieën en cosmetica
Apothekers
Groothandel in farmaceutische producten